Skip to main content
. 2017 Feb 21;8(13):21754–21769. doi: 10.18632/oncotarget.15567

Figure 7. The combined Celecoxib/Cetuximab treatment alters the nuclear levels of β-catenin and FOXM1 in CRC cells.

Figure 7

To determine if FOXM1 promotes the nuclear accumulation of β-Catenin in A. Caco-2, HT-29 and HCT-116, cells were exposed to the indicated treatments (cetuximab, CTX; celecoxib, CXB) for 6 hours and then cytosolic and nuclear fractions were obtained. The expression of FOXM1 and β-catenin was analyzed by immunoblotting and the immunodetection of tubulin and TFIIB were included as loading controls for cytosolic and nuclear fractions, respectively. B. The corresponding densitometric analyses are also shown. Data are means ± SEM of three independent experiments (*p <0.05, compared with the control; # p<0.05, compared with cetuximab-treated cells).